Skip to site menu Skip to page content

Daily Newsletter

08 October 2025

Daily Newsletter

08 October 2025

Vektor Medical’s arrhythmia mapping system receives CE mark

The CE mark certification was achieved through the BSI, in accordance with the EU Medical Device Regulation.

Prasanna Gullapalli October 08 2025

US-based Vektor Medical has secured the CE mark for its non-invasive vMap System, designed to assist physicians in the treatment of individuals with arrhythmias.

The system utilises AI to convert data from a standard 12-lead electrocardiogram into three-dimensional maps that pinpoint the source of arrhythmias, such as ventricular tachycardia and atrial fibrillation, all within less than a minute.

The certification was achieved through the British Standards Institution (BSI), in accordance with the EU Medical Device Regulation.

vMap is designed to integrate with existing technologies in medical laboratories, providing a solution that enhances clinical workflows and offers physicians an understanding of arrhythmia mechanisms.

Furthermore, it is said to amplify the pulsed field ablation (PFA) impact by offering electrophysiologists rapid insights into the ablation targets during the planning phase of the procedure and within the electrophysiology laboratory.

According to the company, the system, which had been exclusively used in the US before, has been employed across more than 30 hospitals.

Vektor Medical CEO Rob Krummen said: “Securing CE Mark under the EU Medical Device Regulation, one of the most rigorous regulatory frameworks in the world, underscores the strength of our technology and quality systems.

“With regulatory approvals now in place in the US and Europe, we are well positioned to accelerate adoption and expand access to this innovation globally.”

In September 2025, the company announced the enrolment of the first subject in the VITAL-EP trial by Ascension St. Vincent’s, US.

This trial is tailored to assess the vMap-guided workflow optimisation and efficacy of ablation procedures.

It will assess various endpoints, as well as key efficiency measures like duration of the procedure and fluoroscopy usage.

The study, which includes retrospective as well as prospective cohorts, plans to enrol a total of 110 subjects across five sites.

Last year, the company secured $16m in Series A financing to further the expansion of vMap.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close